UK markets closed
  • NIKKEI 225

    +679.62 (+2.38%)

    +133.42 (+0.47%)

    +0.06 (+0.10%)

    -10.70 (-0.60%)
  • DOW

    -188.88 (-0.55%)

    -1,389.40 (-3.43%)
  • CMC Crypto 200

    +25.90 (+2.08%)
  • ^IXIC

    -43.01 (-0.31%)
  • ^FTAS

    +29.40 (+0.75%)

Global TNF Alpha Inhibitors Market Report 2020: Market is Expected to Recover and Reach $42.86 Billion in 2023 - Long-term Forecast to 2025 & 2030

Research and Markets
·5-min read

Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to's offering.

The global TNF alpha inhibitors market is expected to decline from $40.66 billion in 2019 to $39.01 billion in 2020 at a compound annual growth rate (CAGR) of -4.06%.

Major players in the TNF alpha inhibitors market are AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A, Novartis International AG, Pfizer, Inc., Merck & co., Inc., Janssen Biotech, Ablynx, and Momenta Pharmaceuticals.

The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $42.86 billion in 2023 at a CAGR of 3.18%.

The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-) inhibitors by entities that manufacture TNF alpha inhibitors. TNF alpha inhibitors are a group of medicines that conquer the body's natural response to TNF, a protein produced by white blood cells, involved in early inflammatory events. These are important treatments in the number of inflammatory conditions including spondylarthritis, psoriasis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD).

North America was the largest region in the TNF alpha inhibitors market in 2019. Asia-Pacific is expected to be the fastest-growing region during the forecast period.

In May 2020, AbbVie Inc, a US-based biopharmaceutical company, completed the acquisition of Allergan plc for an amount of $63 billion. The acquisition is expected to expand and diversify AbbVie Inc's revenue base and its existing immunology portfolio. Allergan plc is an Ireland-based pharmaceutical company engaged in manufacturing and marketing drugs and medical devices in the areas of the central nervous system, eye care, medical aesthetics, and gastroenterology.

The TNF alpha inhibitors market covered in this report is segmented by drug into remicade (infliximab); enbrel (etanercept); humira (adalimumab); cimzia (certolizumab pegol); simponi (golimumab). It is also segmented by route of administration into oral; subcutaneous; intravenous; others and by disease type into inflammatory bowel disease; psoriatic arthritis; ulcerative colitis (UC); rheumatoid arthritis; ankylosing spondylitis; others.

The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market. The multiple adverse effects of TNF alpha inhibition identified by clinical trials and post-marketing surveillance include injection site reactions, neutropenia, infusion reactions, and infections.

According to the U.S. Food and Drug Administration (FDA), TNA alpha inhibitors can cause serious infections in people with weaker immune systems or low resistance levels. The infections can be bacterial, mycobacterial, fungal, and viral leading to various diseases such as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. These side effects force patients to prefer alternatives such as non-TNF biologics, which hampers the growth of the market.

The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitors market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology and rheumatology for the treatment of various immune-mediated inflammatory diseases.

Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases for ulcerative colitis per 100,000 person-years and 0.1-16 cases for Crohn's disease per 100,000 person-years, and overall, IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors contributing to the growth of the market.

Key Topics Covered:

1. Executive Summary

2. TNF Alpha Inhibitors Market Characteristics

3. TNF Alpha Inhibitors Market Size and Growth
3.1. Global TNF Alpha Inhibitors Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global TNF Alpha Inhibitors Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. TNF Alpha Inhibitors Market Segmentation
4.1. Global TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

  • Remicade (infliximab)

  • Enbrel (etanercept)

  • Humira (adalimumab)

  • Cimzia (certolizumab pegol)

  • Simponi (golimumab)

4.2. Global TNF Alpha Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

  • Oral

  • Subcutaneous

  • Intravenous

  • Others

4.3. Global TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

  • Inflammatory Bowel Disease

  • Psoriatic Arthritis

  • Ulcerative Colitis (UC)

  • Rheumatoid Arthritis

  • Ankylosing Spondylitis

  • Others

5. TNF Alpha Inhibitors Market Regional and Country Analysis
5.1. Global TNF Alpha Inhibitors Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global TNF Alpha Inhibitors Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

  • AbbVie Inc.

  • Amgen Inc.

  • Johnson & Johnson Services Inc.

  • UCB S.A

  • Novartis International AG

  • Pfizer Inc.

  • Merck & co. Inc.

  • Janssen Biotech

  • Ablynx

  • Momenta Pharmaceuticals

  • Celgene Corporation

  • GlaxoSmithKline

  • Sanofi-Aventis

  • Zydus Cadila

  • HanAll Biopharma

  • AryoGen Biopharma

  • LG Life Sciences

  • Samsung Bioepis

  • Bionovis

  • Celltrion Healthcare

  • CASI Pharmaceuticals

  • EPIRUS Biopharmaceuticals

  • HanAll Biopharma

  • Intas Pharmaceuticals

  • LEO Pharma

  • MedImmune

  • Momenta Pharmaceuticals

  • Reliance Life Sciences

  • Sandoz

  • Biogen

  • AstraZeneca

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900